- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04536350
Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS
January 16, 2024 updated by: Prof. Dr. Jörg Leuppi
Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS: A Randomized, Placebo Controlled, Multicenter Trial
The world is currently experiencing a coronavirus (CoV-2) pandemic.
A new (SARS)-CoV infection epidemic began in Wuhan, Hubei, China, in late 2019; originally called 2019- nCoV the virus is now known as SARSCoV- 2 and the disease it causes COVID-19.
Previous CoV epidemics included severe acute respiratory syndrome (SARS)-CoV, which started in China in 2003 and Middle East respiratory syndrome (MERS)-CoV in the Middle East, which started in 2012.
The mortality rates were >10% for SARS and >35% for MERS.
The direct cause of death is generally due to ensuing severe atypical pneumonia and ensuing acute respiratory distress syndrome (ARDS).
Pneumonia also is generally the cause of death for people who develop influenza, although the mortality rate is lower (1%-3% for the influenza A H5N1 pandemic of 1918-1919 in the United States).
Risk factors for a poor outcome of SARS-CoV-2 infection have so far been found to include older age and co-morbidities including chronic cardiovascular and respiratory conditions and current smoking status.
In May 2020, the FDA authorized the emergency use of remdesivir for treatment of COVID-19 disease based on topline date of two clinical trials, even though an underpowered clinical trial did not find significant improvement in COVID- 19 patients treated with remdesivir.
Nevertheless, remdesivir is the first and so far, only approved treatment for COVID-19.
Additionally further trials and clinical observations have not found a significant benefit of other antiviral drugs.
Although the results of several studies are still pending, there is still a desperate need for an effective, safe treatment for COVID-19.
Aviptadil, which is a synthetic form of Human Vasoactive Intestinal Polypeptide (VIP), might be beneficial in patients at risk of developing ARDS.
Nonclinical studies demonstrate that VIP is highly concentrated in the lung, where it reduces inflammation.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
About 20% of individuals with Corona Virus disease (COVID-19) experience more severe disease characterized by significant respiratory symptoms including acute respiratory distress syndrome (ARDS).
ARDS is a known lethal complication due to its low blood oxygenation levels and may result in organ failure.
Until now, there are no specific vaccines or therapeutic drugs targeting SARS-CoV-2, alternative therapeutic interventions are needed to prevent and ameliorate respiratory conditions associated with COVID-19 to effectively reduce mortality and prevent ICU admissions.
Aviptadil, which is a synthetic form of Human Vasoactive Intestinal Polypeptide (VIP), might be beneficial in patients at risk of developing ARDS.
Nonclinical studies demonstrate that VIP is highly concentrated in the lung, where it prevents N-methyl-D-aspartate (NMDA)-induced caspase-3 activation, inhibits IL-6 and TNFa production and protects against HCl-induced pulmonary edema.
Further, in animal model systems of lung injury in mice, rats, guinea pigs, sheep, swine and dogs, Aviptadil was shown to restore barrier function at the endothelial/alveolar interface and to protect the lung and other organs from failure.
In Europe, Aviptadil is approved for human use and has been shown to be safe in phase II trials for sarcoidosis, pulmonary fibrosis, bronchospasm, erectile dysfunction as well as in a phase I trial in ARDS in the past two decades.
In the US, VIP has been given FDA Orphan Drug Designation for the treatment of ARDS and was admitted to the FDA Corona Virus Technology Accelerator Program.
In a phase I trial of Aviptadil performed by Sami Said in the early 2000s, eight patients with severe ARDS on mechanical ventilation were treated with ascending doses of intravenous VIP.
Seven patients (88%) were successfully extubated and were alive at the five day time point.
Six (75%) left the hospital and one (13%) died of an unrelated cardiac event.
A phase II clinical trial using intravenous Aviptadil in patients with COVID-19 infection and ARDS has begun.
Further, a phase II/III clinical trial will study the effect of inhaled Aviptadil for the treatment of non-acute lung injury in COVID- 19 and begins in June 2020.
In Europe, two phase II trials of Aviptadil have been conducted.
Further, studies with healthy volunteers have shown that inhaled Aviptadil is well tolerated with few adverse effects.
Study Type
Interventional
Enrollment (Actual)
83
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
St.Gallen, Switzerland, 9007
- Cantonal Hospital St.Gallen
-
-
BL
-
Liestal, BL, Switzerland, 4410
- Cantonal Hospital Baselland Liestal
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- COVID-19 infection diagnosed
- Risk factors for the development of an ARDS according to an adapted EALI (early acute lung injury score) ≥ 2 Points (with at least one point from the EALI score)
EALI Score:
- 2-6l O2 supplementation to achieve a SaO2>90%: 1 point
- >6l O2 supplementation to achieve a SaO2>90%: 2 points
- Respiratory rate ≥ 30/min: 1 point
- Immunosuppression: 1 Point
Modification (for adapting for risk factors for ARDS in SARS-CoV-2 affected patients
- Arterial hypertension: 1 point
- Diabetes: 1 point
Fever > 39°C: 1 point
- Age > 18 years
- Ability to adequate compliance with the inhalation manoeuvre
- Ability to sign the informed consent
Exclusion Criteria:
- Known or highly suspected bacterial infection (antibiotic treatment to avoid bacterial superinfection may be allowed)
- PCT ≥ 1μg/l
- Mechanical ventilation
- Inability to conduct inhalation therapy
- Hemodynamic instability with requirement of vasopressor therapy
- Severe comorbidities interfering with the safe participation at the trial according to the treating physician
- Pregnancy
- Systemic immunosuppression
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aviptadil Treatment
Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
|
Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
|
Placebo Comparator: Placebo Treatment
Participants in the control group will receive an Inhalation of 0.9% NaCl solution three times a day for 10 days
|
Patiens will receive Standard care plus 0.9% NaCl solution three times a day for ten days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to clinical improvement
Time Frame: Randomization until discharge from hospital but up to maximum 28 days
|
Time to clinical improvement of a decrease of at least two points on a seven-point ordinal scale of clinical status or discharged alive from hospital. The seven-point scale consists of the following categories:
|
Randomization until discharge from hospital but up to maximum 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of mechanical ventilation
Time Frame: Randomization until discharge from hospital up to maximum 28 days
|
Frequency of Patient who need mechanical ventilation during hospital stay
|
Randomization until discharge from hospital up to maximum 28 days
|
Oxygen supplementation
Time Frame: Randomization until discharge from hospital up to maximum 28 days
|
Time requiring oxygen supplementation
|
Randomization until discharge from hospital up to maximum 28 days
|
SaO2
Time Frame: Randomization until discharge from hospital up to maximum 28 days
|
Slope in SaO2
|
Randomization until discharge from hospital up to maximum 28 days
|
FiO2
Time Frame: Randomization until discharge from hospital but up to maximum 28 days
|
Slope in FiO2
|
Randomization until discharge from hospital but up to maximum 28 days
|
C-reactive Protein
Time Frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days
|
Slope in C-reactive Protein
|
measured at baseline, at least every 7 days and at discharge up to maximum 28 days
|
Neutrophile
Time Frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days
|
Neutrophile ratio
|
measured at baseline, at least every 7 days and at discharge up to maximum 28 days
|
lymphocyte
Time Frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days
|
lymphocyte ratio
|
measured at baseline, at least every 7 days and at discharge up to maximum 28 days
|
Interleukine 6
Time Frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days
|
Interleukine 6 level
|
measured at baseline, at least every 7 days and at discharge up to maximum 28 days
|
Procalcitonin
Time Frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days
|
Procalcitonin level
|
measured at baseline, at least every 7 days and at discharge up to maximum 28 days
|
Frequency of Multi organ dysfunction Syndrome (MODS)
Time Frame: Randomization until discharge from hospital up to maximum 28 days
|
Frequency of Patient who showed a multi organ dysfunction Syndrome during Hospital stay
|
Randomization until discharge from hospital up to maximum 28 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospitalization
Time Frame: randomization till discharge of hospital up to 28 days
|
duration of hospitalization in survivors
|
randomization till discharge of hospital up to 28 days
|
treatment initiation to death
Time Frame: Treatment initiation to death up to maximum 28 days
|
Time from treatment initiation to death
|
Treatment initiation to death up to maximum 28 days
|
Blood pressure
Time Frame: Daily until discharge up to maximum 28 days
|
Blood pressure will be assessed daily in mmHg
|
Daily until discharge up to maximum 28 days
|
Heart rate
Time Frame: Daily until discharge up to maximum 28 days
|
Heart rate will be assessed daily in bpm
|
Daily until discharge up to maximum 28 days
|
Respiratory rate
Time Frame: Daily until discharge up to maximum 28 days
|
Respiratory rate will be assessed daily in Counts per minute
|
Daily until discharge up to maximum 28 days
|
Body temperature (auricular) in °C
Time Frame: Daily until discharge up to maximum 28 days
|
Body temperature (auricular) will be assessed daily in °C
|
Daily until discharge up to maximum 28 days
|
Pulse oximetry
Time Frame: Daily until discharge up to maximum 28 days
|
Pulse oximetry will be assessed daily in %
|
Daily until discharge up to maximum 28 days
|
Glasgow Coma Scale
Time Frame: Daily until discharge up to maximum 28 days
|
Glasgow Coma Scale will be assessed daily The lowes possible score is 3 = deep coma or death The highest possible score is 15 = Fully awake
|
Daily until discharge up to maximum 28 days
|
Dispnea and caugh
Time Frame: Randomization until discharge from hospital up to maximum 28 days
|
Visual analogue scale for dyspnea and cough as patient-related outcome parameter
|
Randomization until discharge from hospital up to maximum 28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jörg D Leuppi, Professor, Cantonal Hosptal, Baselland
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 18, 2021
Primary Completion (Actual)
June 14, 2023
Study Completion (Actual)
June 14, 2023
Study Registration Dates
First Submitted
August 21, 2020
First Submitted That Met QC Criteria
September 1, 2020
First Posted (Actual)
September 2, 2020
Study Record Updates
Last Update Posted (Estimated)
January 18, 2024
Last Update Submitted That Met QC Criteria
January 16, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-01902
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Aviptadil 67μg
-
Centurion PharmaKlinar CROCompleted
-
NeuroRx, Inc.RecruitingSARS-CoV 2 | COVID | ARDS | Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Dyspnea | ALIUnited States
-
APR Applied Pharma Research s.a.WithdrawnSARS-CoV 2 | COVID | ARDS | Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Dyspnea | ALI
-
APR Applied Pharma Research s.a.Cavendish Impact Foundation; Clinigen, Inc.; Nephron Pharmaceuticals, Inc.No longer availableCritical COVID-19 With Respiratory FailureUnited States
-
APR Applied Pharma Research s.a.Lavin Consulting, LLCCompletedAcute Lung Injury | Corona Virus Infection | Acute Respiratory Distress Syndrome (ARDS) | Critical COVID-19 With Respiratory FailureUnited States
-
National Institute of Allergy and Infectious Diseases...National Heart, Lung, and Blood Institute (NHLBI); Gilead Sciences; University... and other collaboratorsCompleted
-
QuantumLeap Healthcare CollaborativeM.D. Anderson Cancer Center; University of Colorado, Denver; University of Pennsylvania and other collaboratorsRecruitingCOVID-19United States